Exhibit 1.1

《包括性合同：大自然药业股份有限公司与北日本制药的资本与战略合作合同》

Strategic Cooperation Agreement by and between Universe Pharmaceuticals INC and Kitanihon Pharmaceutical Co., Ltd.

甲方：大自然药业股份有限公司

Party A: Universe Pharmaceuticals INC

英文名：Universe Pharmaceuticals INC

English Name: Universe Pharmaceuticals INC

注册号：

Registration No.:

企业官网网址：www.dzrzy.com

Corporate Website: www.dzrzy.com

纳斯达克上市代码：upc

Nasdaq Listing Code: upc

法定代表人：赖刚

Legal Representative: Lai Gang

英文名：Lai Gang

English Name: Lai Gang

中国居民身份证号码：

Chinese Resident ID Card No.:

企业地址：Vistra (Cayman) Limited P.O.Box 31119,Grand Pavillion,Hibiscus Way,802 West Bay Road,Grand Cayman, KY1-1205

Business Address: Vistra (Cayman) Limited P.O. Box 31119, Grand Pavillion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205

乙方：北日本制药株式会社

Party B: Kitanihon Pharmaceutical Co., Ltd.

日文名：キタニホンセイヤクカプシキカイシャ

Japanese Name: キタニホンセイヤクカプシキカイシャ

注册号码：

Registration No.:

企业官网网址：www.999jp.co.jp

Corporate Website: www.999jp.co.jp

法人代表：西村一郎

Legal Representative: Nishimura Ichiro

英文名：Nishimura Ichiro

English Name: Nishimura Ichiro

日本国护照号码：

Japanese Passport No.:

企业地址：（日本国）富山県中新川郡上市町若杉55

Business Address: 55, Wakasugi, Kamiichi-machi, Nakaniikawa-gun, Toyama, Japan

合作签署背景：

Background of Cooperation:

甲方是在美国纳斯达克上市的专注于中成药及药酒研发、制造、营销的医药企业；乙方是拥有80年以上历史在日本及亚洲具有代表性的汉方药研发、制造、营销的企业。为了更好地发挥双方在中日两国所具有的原料药材、制药技术、新药研发、品牌影响及市场销售的优势，更好地整合两国的政策、金融、法律在传统医药保护方面的资源，甲乙双方经过充分调研、深入协商，决定就：1、相互取得对方企业股权，形成坚强的责、权、利共同体；2、共同开拓以中、日双品牌，日本标准、日本技术、日本指导、日本监制、中国制造为特征的高端中成药、汉方药的中国市场、日本市场、东南亚市场、一带一路沿线国市场；3、持续加强对以植物由来的医药及大健康产品的研发、不断提升品牌的内涵和竞争力、切实储备企业后续长期发展的底力，深度强化资本与战略合作，达成以下合作内容并签定此合同：

Party A is a NASDAQ-listed pharmaceutical company specializing in R&D, manufacture and marketing of Chinese patent medicines and medicinal liquor; Party B is a representative enterprise specializing in R&D, manufacture and marketing of Kampo medicine with a history of over 80 years in Japan and Asia. In order to give full play to the advantages of both parties in raw materials, pharmaceutical technology, new drug R&D, brand influence and marketing in China and Japan, and to better integrate the policies, financial and legal resources of China and Japan in traditional medicine protection, Party A and Party B have decided, after thorough research and in-depth consultation, to reach the following cooperation and sign this Contract regarding: 1. Mutual acquisition of each other’s equity to form a strong community of responsibility, power and benefit; 2. Joint expansion of the Chinese market, the Japanese market, the Southeast Asian market and the markets of countries along the Belt and Road of high-end Chinese patent medicine and Kampo medicine characterized by Chinese and Japanese dual brands, Japanese standards, Japanese technology, Japanese guidance, Japanese supervision and manufacture in China; 3. Continuous strengthening of R&D of plant-based medicine and big health products, constant improvement of brand connotation and competitiveness, effective reserves for the enterprise’s subsequent long-term development, and deep strengthening of capital and strategic cooperation:

一、合同组成

I. Composition of the Contract

本合同分别由《商羽控股集团有限公司股权转让合同》、《北日本制药株式会社股权认购合同》和《大自然药业股份有限公司和北日本制药株式会社合作建设国际制造基地的合同》等叁份从属合同共同组成（简称：本合同），叁份子合同虽分别签署但互为存在前提和组成部分，除经甲乙双方另行协商签署新的相关合同外，叁份子合同均无分离或单独使用的法律效力。

This Contract is composed of three subordinate contracts, namely the Equity Transfer Contract of Sununion Holding Group Ltd., Equity Subscription Contract of Kitanihon Pharmaceutical Co., Ltd. and Contract for the Cooperation in International Manufacturing Base Construction between Universe Pharmaceuticals INC and Kitanihon Pharmaceutical Co., Ltd. (hereinafter referred to as the Contract). The three sub-contracts are signed separately but are prerequisites and components of each other, none of which shall have the legal effect of separation or separate use unless a new relevant contract is signed by both parties through separate negotiation.

二、合同顺序

II. Order of the Contract

本合同的完成顺序为：1、甲方在完成签署合同后在最短的有效时间内，完成《商羽控股集团有限公司股权转让合同》所必须的商业登记和新的股东名单登记；2、乙方在甲完成上述”1”款所示内容之后最短的有效时间内，完成《北日本制药株式会社股权认购合同》所必须的商业登记和新的股东名单登记。3.签订本合同后立即开展国际制造基地项目立项、政策落地、规划设计等项目启动工作，并快速推进项目建设。

The order of completion of the Contract shall be as follows: 1. Party A shall, within the shortest effective time after the signing of the Contract, complete the business registration and the registration of new list of shareholders necessary for the Equity Transfer Contract of Sununion Holding Group Ltd.; 2. Party B shall, within the shortest effective time after Party A completes the contents set forth in paragraph 1 above, complete the business registration and the registration of new list of shareholders necessary for the Equity Subscription Contract of Kitanihon Pharmaceutical Co., Ltd.; 3. The startup work of the international manufacturing base project, including initiation, policy implementation, planning and design, shall be carried out immediately after the signing of the Contract, and the project construction shall be accelerated.

三、存续条件（1）

III. Conditions of Existence (1)

本合同以双方在子合同中具体规定的在共同在中国江西省井冈山经济开发区（或经甲乙双方经过协商达成共识的中国境内其他省份、地区）建设通过中国GMP认证和日本CGMP认证的中成药、汉方药国际生产基地，其产品以中、日双品牌，日本标准、日本技术、日本指导、日本监制、中国制造为特征，完成：1.中国境内髙端中医药销售；2.出口日本；3.出口东南亚及一带一路沿线国”的国际中成药（汉方药）生产制造基地项目的启动与续存为续存的前提条件。

The Contract shall exist subject to the commencement and continuation of the international manufacturing base for Chinese patent medicine and Kampo medicine certified by GMP in China and CGMP in Japan jointly built by both parties, as specified in the sub-contracts, in Jinggangshan Economic Development Zone, Jiangxi Province, China (or other provinces or regions in China as agreed upon by both parties after negotiation), with products characterized by Chinese and Japanese dual brands, Japanese standards, Japanese technology, Japanese guidance, Japanese supervision and manufacture in China, to complete: 1. Sales of high-end traditional Chinese medicine within China; 2. Export to Japan; 3. Export to Southeast Asia and countries along the Belt and Road.

四、存续条件（2）

IV. Conditions of Existence (2)

本合同的全部内容均以符合甲乙双方及甲乙双方所有子公司所在国的法律规定、政策要求，不存在违法记录、不存在未处理完成的违规记录、不存在法律纠纷、不存在恐怖与支持恐怖组织与国家、不存在与黑恶势力及其他反社会势力相关联、不存在洗钱犯罪行为为前提条件。

All the contents of the Contract shall be subject to the prerequisites of compliance with the laws and regulations and policy requirements of the countries where all subsidiaries of Party A and Party B are located, absence of illegal records, absence of uncompleted processing of violation records, absence of legal disputes, absence of terrorist and support for terrorist organizations and countries, absence of association with underworld and other anti-social forces, and absence of criminal acts of money laundering.

凡涉及违反违背甲乙双方所在国及甲乙双方所有子公司所在国法律规定、政策限制条款，均以服从甲乙双方所在国及甲乙双方所有子公司所在国的法律规定、政策限制内容为上法及准绳。

Any violation of the laws and regulations and policy restrictions in the countries where both parties are located and in the countries where all subsidiaries of both parties are located shall be subject to the laws and regulations and policy restrictions in the countries where both parties are located and in the countries where all subsidiaries of both parties are located.

五、排他性

V. Exclusivity

甲乙双方一致强调：本合同一经签署，在存续其间，所有标的业务具有严格排他性。其中在本项目未取得日本国《医药品外国生产业者认定证》（俗称日本CGMP认证）和未按日本PMDA要求在业者认证之后，将具体的产品有序的完成全部转移和品种认证之前，乙方委托天津和治药业集团股份有限公司和广东悦康生物制药有限公司的生产和出口业务，作为期间过渡性安排，不受本条款限制。

Party A and Party B agree and emphasize that all subject business is strictly exclusive once the Contract is signed and during its existence. Among them, before the project has obtained the Certificate of Foreign Manufacturer of Pharmaceutical Products of Japan (commonly known as Japanese CGMP certification) and before the orderly completion of all transfers and variety certification of specific products after the practitioner certification as required by Japanese PMDA, the production and export operations entrusted by Party B to Tianjin Hezhi Pharmaceutical Group Co. Ltd. and Guangdong Youcare Biopharmaceutical Co. Ltd. are not subject to this clause as a transitional arrangement during the period.

六、适用法律以及违约与争议的处理

VI. Applicable Law and Settlement of Breach of Contract and Dispute

1、当甲乙双方任何一方不履行或明显拖延履行本合同所规定的责任与义务，并在另一方口头督促与书面警告提出后仍然不履行或明显拖延履行本合同所规定的责任与义务时，被视为违约行为；

1. Any party who fails to perform or significantly delays in the performance of its responsibilities and obligations hereunder, and continues to fail to perform or significantly delay in the performance of its responsibilities and obligations hereunder after verbal urging and written warning from the other party, shall be deemed to be in breach of the Contract;

2、当违约行为发生后，被违约方向违约方口头督促与书面警告三个月后，违约方仍无实效性履行本合同行为时，被违约方有权按本合同第七条第4款向违约方提出经济索赔，违约方依据本合同第七条第4款被违约方支付经济索赔。

2. In case of a breach of contract, if the breaching party still fails to effectively perform the Contract after three months from the date of receiving verbal urging and written warning from the non-breaching party, the latter shall have the right to make an economic claim against the former in accordance with Article 7, paragraph 4 hereof, and the breaching party shall pay the economic claim to the non-breaching party in accordance with Article 7, paragraph 4 hereof.

3、甲乙双方一致确定：本合同的订立、生效、解释、履行、及争议之解决等适用《新加坡国际仲裁法》。对于一切因履行本合同所发生的或与本合同相关的本合同所规定内容以外的争议，均应通过反复协商、真诚沟通、友好妥善解决。如果确实遇到无法通过协商而解决的争议，由争议提起方向被争议提起方所在地或第三方新加坡的国际仲裁机构提起仲裁。

3. Both parties agree that Singapore International Arbitration Act shall apply to the conclusion, entry into force, interpretation, performance and settlement of disputes of the Contract. All disputes arising from the performance of the Contract or in connection herewith other than those specified herein shall be settled amicably and properly through repeated negotiation and sincere communication. In case of a dispute that cannot be settled through negotiation, the disputing party shall submit the dispute to an international arbitration institution at the seat of the disputed party or in third-party Singapore for arbitration.

双方同意接受国际仲裁机构的仲裁结果。

Both parties agree to accept the award of the international arbitration institution.

七、合同的终止与解除

VII. Termination and Rescission of the Contract

甲乙双方一致同意：

Both parties agree that:

1、在本合同履行过程中，如因不可抗力（包括战争；自然灾害如地震等；政府行为如征收、征用；社会异常事件，如疫情、罢工、骚乱等）及其他法律规定的不可抗拒原因，导致的合同目的无法实现，被迫延期或终止本合同时，不追究对方责任；

1. In the course of performance of the Contract, if the contract purpose cannot be achieved due to force majeure (including war; natural disasters such as earthquake; government actions such as expropriation, requisition; abnormal social events such as epidemic, strike, riot, etc.) and other irresistible reasons as provided by law, the other party will not be investigated and held responsible for the forced extension or termination of the Contract.

2、在本合同履行过程中，如其中一方有下列情形之一，以及其他法律规定可以因其而导致合同另一单方解除合同的情况时，另一方有权单方解除本合同：

2. In the course of performance of the Contract, the other party shall have the right to unilaterally rescind the Contract if either party has any of the following circumstances, as well as any other circumstances that may cause the other party to unilaterally rescind the Contract as a result of them, as provided by law:

（1）一方企业被查封、转卖或者破产；

(1) The enterprise of one party is seized, resold or bankrupt;

（2）一方企业无论任何原因无法正常运营；

(2) The enterprise of one party fails to operate normally for any reason;

（3）一方出现重大瑕疵包括重大质量瑕疵导致本合同目的无法实现；

(3) The purpose of the Contract cannot be realized due to major defects of one party, including major quality defects;

3、除以上”1、2”中所规定内容之外，甲乙双方均不可要求终止和解除本合同；

3. Neither party shall request to terminate or rescind the Contract except as stipulated in 1 and 2 above;

4、在本合同有效的存续期间内，甲乙双方任何一方无充足理由或足够证据而单独终止、解除本合同或事实上单独终止、解除本合同的，另一方有权提出因履行本合同所发生的实际经济损失2倍的经济索赔，违约方必须依据本条约定支付被违约方的因履行本合同所发生的实际经济损失2倍的经济索赔。

4. If either party unilaterally terminates or rescinds the Contract without sufficient reason or evidence or in fact unilaterally terminates or rescinds the Contract during the valid duration of the Contract, the other party shall have the right to claim for economic loss twice the actual economic loss incurred in the performance of the Contract, and the breaching party shall, in accordance with the provisions of this clause, pay the non-breaching party an economic claim twice the actual economic loss incurred in the performance of the Contract.

八、承诺与保证（1）

VIII. Commitment and Warranty (1)

甲乙双方承诺并保证：其企业及其所有企业经营层管理人员不属于（包括但不限于）：

Party A and Party B undertake and warrant that their enterprises and all their business management personnel are not (including but not limited to):

（1）国际恐怖组织及其关联人员；

(1) International terrorist organizations and their associated persons;

（2）黑社会及其他反社会组织；

(2) Underworld and other anti-social organizations;

（3）制毒、贩毒及关联人员；

(3) Drug manufacturing, drug trafficking and associated persons;

（4）参与洗钱行为；

(4) Involved in money laundering;

（5）拐卖女性儿童及其他侵犯人权；

(5) Abducting women and children and other human rights violations;

（6）伤害保护动物；

(6) Harming protected animals;

（7）污染环境；

(7) Environmental pollution;

（8）各种犯罪；

(8) Various crimes;

（9）失信；

(9) Breach of trust;

（10）危害社会；

(10) Endangering society;

等一切反社会行为的组织及人员。

and all organizations and personnel with anti-social behavior.

九、承诺与保证（2）

IX. Commitment and Warranty (2)

甲乙双方承诺与保证：1.在本合同签署之前，须取得各方董事会、股东大会、法务部门及甲方上巿管理部门各方的同意，以保证本合同得以正常签署与履行。2.在本合同签署之前，双方各自负责与本方所在国及关联国的行政、司法、财税、产业（管理）、药事（管理）及外交等相关部门事先沟通、取得批导，以保障本合同得以顺利履行。

Party A and Party B undertake and warrant that 1. Prior to the signing of the Contract, the consent of the board of directors, the general meeting of shareholders, and the legal departments of both parties and the listing management department of Party A shall be obtained to ensure the normal signing and performance of the Contract. 2. Prior to the signing of the Contract, each party shall be responsible for communicating with and obtaining approval of the administrative, judicial, finance and taxation, industry (management), pharmaceutical (management), foreign affairs and other relevant departments of the country where the party is located and related countries to ensure the smooth performance of the Contract.

十、承诺与保证（3）

X. Commitment and Warranty (3)

甲乙双方承诺并保证：其对为对方及对方国提供的一切资料必须真实有效，绝不欺瞒伪造。必要时可以通过双方国驻对方国使领馆公证。

Party A and Party B undertake and warrant that all information they provide for the other party and the other country shall be true and valid and shall not be falsified. If necessary, the information can be notarized by the embassies and consulates of the two countries in the other country.

十一、承诺与保证（4）

XI. Commitment and Warranty (4)

甲乙双方承诺并保证：充分的理解和尊重并严格遵守对方国法律法规，换位思考，为对方创造良好的工作环境，提供便利的工作条件。

Party A and Party B undertake and warrant that they fully understand, respect and strictly abide by the laws and regulations of the other country, and put themselves in the other’s shoes, to create a good working environment and provide convenient working conditions for the other party.

 十二、本合同与法律政策的关系：如若本合同中任何条款与甲乙双方所在国的法律政策相违，以甲乙双方所在国的法律政策为准。

XII. Relationship between the Contract and laws and policies: If any provision of the Contract is contrary to the laws and policies of the countries where both parties are located, the latter shall prevail.

十三、保秘属性

XIII. Confidentiality

甲乙双方一致保证：对本合同负有不可推卸的保密责任与义务。在不经取得对方书面（包括电子邮件在内）同意的情况下，除法律法规规定的必须向管理机构、司（执）法机关、审计财务管理机构提供的规定限度内的必要的最低限度内的相关信息外，不得将本合同的任何内容泄露给任何第三方（已经公的机构、部门公开发布的信息除外）。

Party A and Party B guarantee that they have unshakable confidentiality responsibilities and obligations hereunder. Without the consent of the other party in writing (including E-mail), no content of the Contract shall be disclosed to any third party (except for those already publicly released by public agencies and departments), with the exception of the minimum necessary information within the prescribed limits that must be provided to the regulatory authorities, judicial (law enforcement) bodies, and audit and financial management agencies, as provided by laws and regulations.

十四、未尽事宜

XIV. Matters not Covered

甲乙双方一致赞同未尽事宜另行协商或通过签署其他合同解决。

Party A and Party B agree that any matters not covered herein shall be settled through negotiation or by signing separate contracts.

十五、合同生效

XV. Entry into Force of the Contract

本合同一式六份，具有同等法律效力，均须经双方法定代表人签署并加盖公章。鉴于本合同事项内容需要经过政府机关以及上市公司董事会、美国纳斯达克证券交易所审批同意，本合同签署之日起即成立，自获得审批之日起生效。

The Contract shall be executed in six copies with equal legal effect, all of which shall be signed and sealed by the legal representatives of both parties. Given that the contents hereunder shall be subject to the approval and consent of government agencies, the board of directors of the listed company and NASDAQ Stock Exchange, the Contract shall be established on the date of signing and enter into force from the date of approval.

甲乙双方各持合同正本一份用以存档。其余用于甲乙双方呈报两国管理机构备案使用。任何一方不得用于任何其他目的。

Party A and Party B shall hold one original copy of the Contract for filing. The rest shall be used by both parties for filing with the regulatory authorities of the two countries. Neither party shall use it for any other purpose.

签约日期：2021年12月1日

Date of Signing: December 1, 2021

甲方：大自然药业股份有限公司

Party A: Universe Pharmaceuticals INC

法人代表：Gang Lai

Legal Representative: Gang Lai

乙方：北日本制药株式会社

Party B: Kitanihon Pharmaceutical Co., Ltd.

法人代表：Nishimura Ichiro

Legal Representative: Nishimura Ichiro

7

Exhibit 1.2

《从属合同之二：北日本制药株式会社股权认购合同》
Share Purchase Agreement by and among Universe Pharmaceuticals INC,
Kitanihon Pharmaceutical Co., Ltd., and Nishimura Ichiro

甲方：大自然药业股份有限公司
Party A: Universe Pharmaceuticals INC

英文名：Universe Pharmaceuticals INC
English Name: Universe Pharmaceuticals INC

注册号：
Registration No.:

企业官网网址：www.dzrzy.com
Corporate Website: www.dzrzy.com

纳斯达克上市代码：upc
Nasdaq Listing Code: upc

法定代表人：赖刚
Legal Representative: Lai Gang

英文名：Lai Gang
English Name: Lai Gang

中国居民身份证号码：
Chinese Resident ID Card No.:

企业地址：Vistra (Cayman)Limited P.O.Box 31119,Grand Pavilion, Hibiscus Way,802 West Bay Road, Grand Cayman, KY1-1205
Business Address: Vistra (Cayman) Limited P.O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205

乙方：北日本制药株式会社
Party B: Kitanihon Pharmaceutical Co., Ltd.

日文名：キタニホンセイヤクカプシキカイシャ
Japanese Name: キタニホンセイヤクカプシキカイシャ

注册号码：
Registration No.:

企业官网网址：www.999jp.co.jp
Corporate Website: www.999jp.co.jp

法人代表：西村一郎
Legal Representative: Nishimura Ichiro

英文名：Nishimura Ichiro
English Name: Nishimura Ichiro

日本国护照号码：
Japanese Passport No.:

企业地址：（日本国）富山県中新川郡上市町若杉55
Business Address: 55, Wakasugi, Kamiichi-machi, Nakaniikawa-gun, Toyama, Japan

丙方：西村一郎
Party C: Nishimura Ichiro

日本国护照号码：
Japanese Passport No.:

日本国住址：
Address in Japan:

电话号码：
Tel:

一、
I.

1、乙方决定在现已发行2628股的基础上增资扩股，具体的金额与额度为：每股38万日元，定向增发464股新股。其份额占增发后新股占总股份的15%。
1. Party B decides to increase capital and expands shares based on the 2,628 shares already issued. The specific amount and quota is 380,000 yen per share and 464 new shares are issued in a private placement. The share accounts for 15% of the total shares after the private placement.

2、甲方同意以每股38万日元价格的价格接受购买乙定向新增发行的464股股份。
2. Party A agrees on the purchase of 464 new shares issued by Party B in a private placement at the price of 380,000 yen per share.

二、甲乙方以企业发展综合性目标为本次增资扩股的前提条件，不以单纯以获得经营资本（资金）为本次增资扩股。甲方须成为乙方的注册股东。
II. Party A and Party B shall take the comprehensive goal of enterprise development as the prerequisite for the said capital increase and share expansion, rather than simply obtaining operating capital (funds) for the capital increase and share expansion. Party A shall become the registered shareholder of Party B.

三、本合同履行的具体方式为：
III. Specific performance method of the Contract is as follows:

按照以上条款，甲方通过银行电汇方式向乙方企业帐户支付乙方定向增资扩股认购金，金额为464 股x38万日元x支出当日银行标准汇率。
Pursuant to the above terms, Party A shall pay to Party B’s enterprise account through bank wire transfer the subscription fee for Party B’s private capital increase and share expansion, in the amount of 464 shares x 380,000 yen x standard bank exchange rate on the day of payment.

四、1、乙方在确认收到甲方的定向增资扩股认购金后，凭新股专款汇入完成的银行汇款凭证，及时向日本国相关管理机构提交新股发行完毕资料留备，并向甲方发放本合同履行完成后的股东名簿以作凭证；
IV. 1. After confirming receipt of Party A’s subscription fee for private capital increase and share expansion, Party B shall, with the bank remittance certificate for the completion of remittance of special funds for the new shares, timely submit to the relevant Japanese regulatory authorities the information on the completion of the new share issuance for filing, and issue to Party A the register of shareholders after the performance of the Contract as a proof.

2、甲方从完成本合同所规定的定向增资扩股认购后，正式成为乙方的股东方，并依据所持比率享受、行使股东权力。
2. Party A shall formally become the shareholder of Party B after the completion of the subscription of the private capital increase and share expansion as stipulated herein, and shall enjoy and exercise the shareholder rights according to the proportion of shares held.

3、乙方股东之一的西村一郎，同意在本合同续存期间，将其所持股份中的乙方股份中的587股（占增发后总股份的19.98%）的表决权，以符合日本相关法律规定的方式赋予甲方行使，以保证甲方取得在日本国《商法》、《会社法》中规定的乙方企业重大事项须得到2/3以上股东同意事项中的1/3否决权的目的。
3. Nishimura Ichiro, one of the shareholders of Party B, agrees to grant Party A the right to exercise the voting rights of 587 shares of Party B (accounting for 19.98% of the total shares after private placement) among the shares he holds during the existence period of the Contract in a manner consistent with the relevant laws of Japan, in order to ensure that Party A obtains the 1/3 veto power of the major matters of Party B’s company which requires the approval of at least 2/3 of the shareholders, as stipulated in the Commercial Code and the Companies Act of Japan.

之后，如果甲方通过其他方式取得乙方更多股权时，西村一郎依据股份比例收减其赋予甲方行使股东表决权的股份数额，直至全部收回，但前提为保证甲方拥有乙方企业重大事项1/3否决权。
Subsequently, if Party A obtains more equity of Party B through other means, Nishimura Ichiro shall deduct the number of shares he grants to Party A to exercise the shareholders’ voting rights according to the proportion of shares until all the shares are withdrawn, provided that Party A has 1/3 veto power on major matters of Party B’s company.

五、甲方须在本合同的前项合作即《从属合同之一：商羽控股集团有限公司股权转让合同》完成后30个工作日内支付本协议第一条约定的增资扩股认购金。如果逾期没有完成，乙方可视甲方为放弃其定向增资扩股的认购权，做出另行安排并且不违反本合同的规定。
V. Party A shall pay the subscription fee for capital increase and share expansion as agreed in Article 1 hereof within 30 working days upon the completion of the cooperation preceding the Contract, namely, Subordinate Contract I: Equity Transfer Contract of Sununion Holding Group Ltd. In case of failure to complete within the time limit, Party B may consider Party A as waiving its right to subscribe for the private capital increase and share expansion and make separate arrangements without violating the provisions hereunder.

六、乙方同意并接受甲方在履行完成本合同之后，乙方董事会由三人组成，甲方向乙方派出董事一人，直接参与乙方的经验管理工作，取得乙方企业信息，保证甲方的投资安全和可以代表甲方行使其所持股份的股东权力。
VI. Party B agrees and accepts that upon Party A’s completion of the Contract, the board of directors of Party B shall be composed of three persons, with a director sent by Party A to Party B to directly participate in Party B’s experience management, obtain Party B’s corporate information, ensure the safety of Party A’s investment and exercise the shareholder’s power on behalf of Party A in respect of the shares it holds.

七、《大自然药业股份有限公司与北日本制药的资本与战略合作合同》为本合同的上位合同，如若本合同中任何条款与《大自然药业股份有限公司与北日本制药的资本与战略合作合同》相违背，以上位合同为准。

VII. The Capital and Strategic Cooperation Contract between Universe Pharmaceuticals INC and Kitanihon Pharmaceutical Co., Ltd. is the superior contract to the Contract. In case any provision hereunder is contrary to the Capital and Strategic Cooperation Contract between Universe Pharmaceuticals INC and Kitanihon Pharmaceutical Co., Ltd., the latter shall prevail.

签约日期：2021年12月1日
Date of Signing: December 1, 2021

甲方：大自然药业股份有限公司
Party A: Universe Pharmaceuticals INC

法人代表：Gang Lai
Legal Representative: Gang Lai

乙方：北日本制药株式会社
Party B: Kitanihon Pharmaceutical Co., Ltd.

法人代表：Nishimura Ichiro
Legal Representative: Nishimura Ichiro

丙方：西村一郎
Party C: Nishimura Ichiro

签字：
Signature:

4

Exhibit 1.3

《从属合同之三：大自然药业股份有限公司与北日本制药株式会社合作建设国际制造基地的合同》
Cooperation Agreement on Manufacturing Facility Construction Project by and between Universe Pharmaceuticals INC and Pharmaceutical Co., Ltd.

甲方：大自然药业股份有限公司
Party A: Universe Pharmaceuticals INC

英文名：Universe Pharmaceuticals INC
English Name: Universe Pharmaceuticals INC

注册号：
Registration No.:

企业官网网址：www.dzrzy.com
Corporate Website: www.dzrzy.com

纳斯达克上市代码：upc
Nasdaq Listing Code: upc

法定代表人：赖刚
Legal Representative: Lai Gang

英文名：Lai Gang
English Name: Lai Gang

中国居民身份证号码：
Chinese Resident ID Card No.:

企业地址：Vistra (Cayman) Limited P.O.Box 31119,Grand Pavillion,Hibiscus Way,802 West Bay Road,Grand Cayman, KY1-1205
Business Address: Vistra (Cayman) Limited P.O. Box 31119, Grand Pavillion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205

乙方：北日本制药株式会社
Party B: Kitanihon Pharmaceutical Co., Ltd.

日文名：キタニホンセイヤクカプシキカイシャ
Japanese Name: キタニホンセイヤクカプシキカイシャ

注册号码：2300-01-004787
Registration No.: 2300-01-004787

企业官网网址：www.999jp.co.jp
Corporate Website: www.999jp.co.jp

法人代表：西村一郎
Legal Representative: Nishimura Ichiro

英文名：Nishimura Ichiro
English Name: Nishimura Ichiro

日本国护照号码：
Japanese Passport No.:

企业地址：（日本国）富山県中新川郡上市町若杉55
Business Address: 55, Wakasugi, Kamiichi-machi, Nakaniikawa-gun, Toyama, Japan

一、甲乙双方共同在中国江西省井冈山经济开发区规划建设能够通过中国GMP认证和日本CGMP认证的中成药、汉方药国际生产基地（简称大自然国际药业基地），基地用地面积为60亩（即39960平方米）以上，甲方负责取得用地。
I. Party A and Party B shall jointly plan and build an international manufacturing base for Chinese patent medicine and Kampo medicine (referred to as Universe International Pharmaceutical Base) in Jinggangshan Economic Development Zone, Jiangxi Province, China, which is capable of passing GMP certification in China and CGMP certification in Japan, with a land area of 60 mu (i.e., 39,960 square meters) or more. Party A shall be responsible for acquiring the land.

二、大自然国际药业基地包括（但不限于）：
II. The Universe International Pharmaceutical Base includes (but is not limited to):

1、生药材前处理、饮片、配方颗粒；
1. Raw medicinal materials pre-treatment, decoction pieces, formula granules;

2、提取；
2. Extraction;

3、制剂；
3. Preparations;

4、包装；
4. Packaging;

5、检验检测中心；
5. Inspection and Testing Center;

6、质量控制中心；
6. Quality Control Center;

7、研发中心；
7. R&D Center;

8、原料仓库；
8. Raw material warehouse;

9、中间体仓库；
9. Intermediate warehouse;

10、成品仓库；
10. Finished product warehouse;

11、行政、培训、会议中心；
11. Administration, Training and Conference Center;

12、健康、生活中心；
12. Health and Life Center;

总建筑面积为不超过39960平方米 x 0.6 x 2。
The gross floor area is not more than 39,960 m² x 0.6 x 2.

三、大自然国际药业基地必须达到中日双方和产品预定出口国家的药事认证法规要求。为确保其对日出口药品的质量，生产体系须保证均一稳定，现代化、自动化、标准化。本着“质量源于设计”的质量管理思路与理念，甲方同意在建设的设计阶段，必须取得并接受乙方指导，以保证建成后取得“日本CGMP”认证即取得日本PMDA的日本国《医药品外国制造业者认定证》；乙方同意从基地设计阶段开始就承担指导、监督、确认的相关责任。
III. The Universe International Pharmaceutical Base must meet the requirements of pharmaceutical certification laws and regulations of both China and Japan and the countries to which the products are intended to be exported. In order to ensure the quality of its pharmaceutical products exported to Japan, the production system must be uniform and stable, modernized, automated and standardized. Party A, based on the quality management idea and concept of “Quality by Design”, agrees to obtain and accept the guidance of Party B during the design stage of the construction, in order to ensure the acquisition of the “Japanese CGMP” certification, i.e., the Japanese PMDA Certificate of Foreign Manufacturer of Pharmaceutical Products, after the completion of the construction; Party B agrees to assume the relevant responsibilities of guidance, supervision and confirmation from the design stage of the base.

四、
IV.

1、甲方负责完成大自然国际药业基地建设的资金投入；
1. Party A shall be responsible for completing the capital investment in the construction of Universe International Pharmaceutical Base;

2、乙方负责指导基地设计的合规（包括中日双方）、布局的合理、工艺的流畅、节能与环保、自动与现代，以确保基地的先进性和效率化的实现。
2. Party B shall be responsible for guiding the base design compliance (including both Chinese and Japanese side), reasonable layout, smooth process, energy saving and environmental protection, automatic and modern, in order to ensure the advancement and efficiency of the base.

五、
V.

1、甲方负责申请并取得大自然国际药业基地所需要的中国药品监管的包括（但不限于）药品生产、剂型、品种等行政审批批件；环评批件；消防批件，保证基地作为制药企业可以进入正常运行、经营；
1. Party A shall be responsible for applying for and obtaining the required Chinese drug regulatory approvals for the Universe International Pharmaceutical Base, including (but not limited to) administrative approvals for drug production, dosage forms and varieties; environmental assessment approvals; and fire safety approvals, in order to ensure that the base can enter normal operation and business as a pharmaceutical enterprise.

2、乙方负责在以上四“1”的基础上和甲方的积极配合下，确保尽快申请并取得日本PMDA的日本国《医药品外国制造业者认定证》（俗称日本CGMP)，并在基地产品可以达到日本药事法规和企业标准的质量保证前提下，将其汉方药产品的生产有序而及时的转移至基地生产并完成出口。
2. Party B shall, on the basis of paragraph 1 in IV above and with the active cooperation of Party A, ensure to apply for and obtain as soon as possible the Japanese PMDA Certificate of Foreign Manufacturer of Pharmaceutical Products (commonly known as Japanese CGMP certification), and, on the premise that the products of the base can meet the quality assurance of Japanese pharmaceutical laws and regulations and enterprise standards, transfer the production of Kampo medicine products to the base in an orderly and timely manner and complete the export.

六、甲方同意：1、以质量为第一的方针，将其原有中药制剂品种转移至大自然国际药业基地进行加工生产，并在适当时机通过“药品上市后再评价”、二次开发等方法和手段，不断提高药品质量；
VI. Party A agrees to: 1. Transfer its original traditional Chinese medicine preparations to the Universe International Pharmaceutical Base for processing and production under the policy of quality first, and to continuously improve the quality of drugs through methods and means such as “post-marketing drug evaluation” and secondary development at an appropriate time;

2、支持乙方科研团队的新药研发，为乙方科研团队的新药研发提供尽可能的支持与帮助，并且愿意成为乙方科研团队的新药研发的产品的落地生产的首选，对其知识产权支付共同认同的费用。
2. Support the new drug R&D by Party B’s scientific research team, i.e., to provide as much support and assistance as possible for the new drug R&D by Party B’s scientific research team, prepare to be the first choice for the production of new drugs developed by Party B’s scientific research team, and pay the agreed-upon fee for its intellectual property rights.

七、乙方同意：
VII. Party B agrees to:

1、对大自然国际药业基地的产品生产进行技术指导和监制生产；
1. Provide technical guidance and supervision for product production at the Universe International Pharmaceutical Base;

2、对于产品质量达到日本标准并经过其书面认同的在中国大陆销售的产品，同意冠以“通过日本PMDA认证企业”、日本“技术指导、监督制造”和双品牌商标标识进行销售。
2. Label the products that meet Japanese standards and are approved in writing for sale in mainland China with the trademark “PMDA Certified Enterprise”, “Technical Guidance, Supervised Manufacturing” in Japan and dual brand logos.

八、大自然国际药业基地产品销售包括（但不限于）：
VIII. Product sales of the Universe International Pharmaceutical Base include (but are not limited to):

1、中国境内以“中日双品牌、通过日本认证企业、北日本制药（株）监制”等品牌、质量优势打入髙端中医药巿场；
1. Entering high-end traditional Chinese medicine market in China with the brand and quality advantages such as “Sino-Japanese dual brand, certified enterprise in Japan, supervised production by Kitanihon Pharmaceutical Co., Ltd.”;

2、出口日本；
2. Export to Japan;

3、出口东南亚及一带一路沿线国市场。
3. Export to Southeast Asia and countries along the Belt and Road.

九、乙方保证在大自然国际药业基地在取得PMDA的日本国《医药品外国制造业者认定证》，生产的各品种均达到日本药事法规和企业标准的质量保证的前提下，按药事法要求将具体产品有序的完成全部转移和品种认证过渡后的十年内，基地出口日本及东南亚、一带一路沿线国的年出口贸易额（金额为人民币）为：
IX. On the premise that the Universe International Pharmaceutical Base has obtained the Japanese PMDA Certificate of Foreign Manufacturer of Pharmaceutical Products and that all varieties it produces meet the quality assurance requirements of Japanese pharmaceutical laws and regulations and enterprise standards, Party B warrants that the annual export trade volume (amount in RMB) of the base to Japan, Southeast Asia and countries along the Belt and Road for the decade after the orderly completion of all transfers and variety certification of specific products as required by the Pharmaceutical Affairs Law will be:

第1事业年度：4千万元；
1st business year: 40 million;

第2 事业年度：8千万元；
2nd business year: 80 million;

第3事业年度：1.6亿元；
3rd business year: 160 million;

第4事业年度：3亿元；
4th business year: 300 million;

第5 事业年度：6亿元；
5th business year: 600 million;

第6事业年度：6.5亿元；
6th business year: 650 million;

第7事业年度：7亿元；
7th business year: 700 million;

第8事业年度：7.5亿元；
8th business year: 750 million;

第9事业年度：8亿元；
9th business year: 800 million;

第10事业年度：8.5亿元；
10th business year: 850 million;

10个事业年度平均4.93亿元。
The average of the 10 business years will be 493 million.

非因甲方原因造成的无法通过日本CGMP认证或业绩无法达标的，则甲方有权取消合作要求乙方退还以无形资产对价获得的相关股权并追究乙方责任；乙方有权要求甲方以完全可以确认的形式回避由乙方无形资产所转化、延伸的成果包括所有接触过乙方无形资产人员的知识、技能增长在内，并有权追究甲方因此而形成相关责任和经济赔偿。
In case of failure to pass the Japanese CGMP certification or failure to meet the performance standards due to non-Party A reasons, Party A shall be entitled to cancel the cooperation, request Party B to return the relevant equity obtained by the consideration of intangible assets and hold Party B accountable; Party B shall be entitled to request Party A to recuse, in a fully identifiable form, the results transformed and extended by Party B’s intangible assets, including the knowledge and skills growth of all personnel who have access to Party B’s intangible assets, and to hold Party A accountable for the related liabilities and financial compensation arising therefrom.

十、
X.

1、甲方保证：在已经明文规定的企业投资补助资金、出口退税以外，利用大自然国际药业基地自身独具的优势条件和无可比性特点，积极争取“一企一策”“一事一议”的政策性资金资源、出口药品奖励资金、新药研发补助资金、国家发改委的配套政策性专项贴息贷款等政策资金等的资助；
1. Party A warrants to take advantage of the unique advantages and incomparable characteristics of the Universe International Pharmaceutical Base to actively seek policy resources such as “one policy for one enterprise” and “one discussion over each matter”, as well as policy funds such as export drug incentives, new drug R&D subsidies, and supporting special discounted loans from the National Development and Reform Commission, in addition to the enterprise investment subsidy funds and export tax rebates that have been explicitly provided for.

2、甲方保证：争取落户于中国江西井冈山的大自然国际药业基地的政策优势条件与广州市黄埔区的生物医药产业的相关政策具有可比性，不出现明显的“政策优势洼地”。如果发生明显的“政策优势洼地”实际情况，甲乙双方可以通过协商另行选择基地落户地点；
2. Party A warrants that the policy advantages of the Universe International Pharmaceutical Base to be settled in Jinggangshan, Jiangxi, China are comparable with those of the biomedical industry in Huangpu District, Guangzhou, without significant “policy depression”. In case of an obvious “policy depression” in practice, both parties may choose another location for settling the base through negotiation.

3、凡因大自然国际药业基地所取得的政策性资金奖励、补助以及取得的优惠措施、条件，归大自然国际药业基地所有，不作为上市母体公司大自然药业股份有限公司（股票代码为UPC）和商羽控股集团资金、资源使用。
3. Any policy incentives, subsidies, preferential measures and conditions obtained by the Universe International Pharmaceutical Base shall be in possession of the Universe International Pharmaceutical Base and shall not be used as the funds and resources by the listed parent company Universe Pharmaceuticals INC (stock code: UPC) and Sununion Holding Group Ltd.

十一、
XI.

1、乙方按日本药事法规和企业管理规定，派相关专家驻大自然国际药业基地参与包括（但不限于）质量认证、检验检测、经营管理等工作，相关费用由乙方承担。甲方同意接受和积极配合日本PMDA和乙方任何形式的定期和不定期检查；
1. Party B shall send relevant experts to the Universe International Pharmaceutical Base to participate in the work including (but not limited to) quality certification, inspection and testing, operation and management according to Japanese pharmaceutical laws and regulations and enterprise management regulations, at its own expense. Party A agrees to accept and actively cooperate with the regular and irregular inspections by Japanese PMDA and Party B in any form;

2、乙方邀请甲乙重要岗位责任人员赴日本学习、培训，积累学习、培训一年以上的经历，相关费用由甲方承担；
2. Party B shall invite personnel responsible for important positions of Party A and Party B to Japan for study and training to accumulate the experience of more than one year, at the relevant expense of Party A;

3、甲乙双方均需为对方派出人员办理签证提供必要的资料并协助其相关手续的办理，督促其尊守现地的法律法规，为其提供安全保障和必要的工作和生活条件，保障其人身安全。
3. Both parties shall provide necessary materials for the personnel they send to apply for visas and assist them in handling relevant procedures, urge them to abide by local laws and regulations, and offer security and necessary working and living conditions to ensure their personal safety.

十二、《大自然药业股份有限公司与北日本制药的资本与战略合作合同》为本合同的上位合同，如若本合同中任何条款与《大自然药业股份有限公司与北日本制药的资本与战略合作合同》相违背，以上位合同为准。

XII. The Capital and Strategic Cooperation Contract between Universe Pharmaceuticals INC and Kitanihon Pharmaceutical Co., Ltd. is the superior contract to the Contract. In case any provision hereunder is contrary to the Capital and Strategic Cooperation Contract between Universe Pharmaceuticals INC and Kitanihon Pharmaceutical Co., Ltd., the latter shall prevail.

签约日期：2021年12月1日
Date of Signing: December 1, 2021

甲方：大自然药业股份有限公司

Party A: Universe Pharmaceuticals INC

法人代表：Gang Lai
Legal Representative: Gang Lai

乙方：北日本制药株式会社
Party B: Kitanihon Pharmaceutical Co., Ltd.

法人代表：Nishimura Ichiro
Legal Representative: Nishimura Ichiro

6

Exhibit 1.4

《从属合同之一：商羽控股集团有限公司股权转让合同》

Share Transfer Agreement by and among Sununion Holding Group Ltd., Kitanihon Pharmaceutical Co., Ltd., and Gang Lai

甲方：商羽控股集团有限公司

Party A: Sunuion Holding Group Ltd.

英文名：SUNUNION HOLDING GROUP LTD.

English Name: SUNUNION HOLDING GROUP LTD.

注册号：

Registration No.:

法定代表人：赖刚

Legal Representative: Lai Gang

英文名：Lai Gang

English Name: Lai Gang

中国居民身份证号码：

Chinese Resident ID Card No.:

企业地址：

Business Address:

乙方：北日本制药株式会社

Party B: Kitanihon Pharmaceutical Co., Ltd.

日文名：キタニホンセイヤクカプシキカイシャ

Japanese Name: キタニホンセイヤクカプシキカイシャ

注册号码：2300-01-004787

Registration No.: 2300-01-004787

企业官网网址：www.999jp.co.jp

Corporate Website: www.999jp.co.jp

法人代表：西村一郎

Legal Representative: Nishimura Ichiro

英文名：Nishimura Ichiro

English Name: Nishimura Ichiro

日本国护照号码：

Japanese Passport No.:

企业地址：（日本国）富山県中新川郡上市町若杉55

Business Address: 55, Wakasugi, Kamiichi-machi, Nakaniikawa-gun, Toyama, Japan

丙方：赖刚

Party C: Lai Gang

英文名：Lai Gang

English Name: Lai Gang

中国居民身份证号码：

Chinese Resident ID Card No.:

中国居民身份证住址：

Address of Chinese ID Card:

电话号码：

Tel:

 商羽控股集团有限公司是在BVI注册成立的控股公司，持有大自然药业股份有限公司（股票代码UPC）59.43%的股权，赖刚作为上市公司的实际控制人，持有商羽控股集团有限公司100%股权，今就项目合作甲、乙、丙三方充分协商达成以下合同条款：

Sununion Holding Group Ltd., a holding company incorporated in BVI, holds 59.43% of the equity of Universe Pharmaceuticals INC (stock code: UPC), and Lai Gang, as the actual controller of the listed company, holds 100% of the equity of Sununion Holding Group Ltd. Party A, B and C hereby agree on the following contract terms through thorough negotiation regarding the project cooperation:

1、 乙方同意将技术、许可权、业务等无形资产作价250万美金注入旗下企业江西大自然制药有限公司。

1. Party B agrees to inject intangible assets such as technology, license rights and business into its subsidiary Jiangxi Universe Pharmaceuticals Co., Ltd. at a price of USD 2.5 million.

2、关于对乙方无形资产的评估，以《北日本制药株式会社委估无形资产评估报告书（海润评报字【2015】第15309号》为基础，甲乙丙三方均认同乙方的无形资产（包括但不限于报告书的内容）具有250万美元的价值。

2. The evaluation of intangible assets of Party B is based on the Evaluation Report on Intangible Assets Entrusted by Kitanihon Pharmaceutical Co., Ltd. (H.R.P.B.Z. [2015] No. 15309), and Party A, B and C all agree that intangible assets of Party B (including but not limited to the content of the report) have a value of USD 2.5 million.

3、本合同中所涉及到的乙方无形资产具体为：

3. The intangible assets of Party B involved in the Contract include specifically the following:

1、乙方的先进企业综合管理经验和对甲方重要岗位的人员培训；

1. Party B’s advanced enterprise integrated management experience and personnel training for Party A’s important positions;

2、相关药品（包括但不限于汉方药）的研究开发技术、生产制造技术、分析检测技术、质量管理技术、药物警戒技术、市场营销技能；

2. R&D technology, manufacturing technology, analysis and testing technology, quality management technology, pharmacovigilance technology and marketing skills of related drugs (including but not limited to Kampo medicine);

3、乙方在日本国的注册商标、品牌、社号以及乙方包括株式会社化之前时期在内的”百年企业”知名度、影响力在中国大陆（不包括港、澳、台特别行政区和地区在内）境内医药领域的使用权；

3. The right to use Party B’s registered trademarks, brands and company registration number in Japan, as well as Party B’s reputation and influence as a “century-old enterprise”, including the period prior to its incorporation, in the pharmaceutical field in mainland China (excluding Hong Kong, Macau and Taiwan Special Administrative Regions and regions).

4、依据乙方的历史品牌体系、生产制造经验、检验检测标准、药物警戒管理等综合药品管理技术，向日本国政府申请并获得批准的《日本国医药品海外制造业者认定证》等特殊属性专业资格资质，以及药品种批准文号、许可的使用权；

4. Applying for and obtaining from the Japanese government the special attribute professional qualifications such as the Certificate of Foreign Manufacturer of Pharmaceutical Products of Japan and the right to use the drug approval number and licenses based on Party B’s historical brand system, manufacturing experience, inspection and testing standards, pharmacovigilance management and other integrated pharmaceutical management techniques.

5、以乙方为依托代理甲方在日本厚生劳动省PMDA取得的《日本国医药品海外制造业者认定证》的维护、更新和存续；

5. Acting as an agent based on Party B for the maintenance, renewal and continuation of the Certificate of Foreign Manufacturer of Pharmaceutical Products of Japan obtained by Party A from the PMDA of the Ministry of Health, Labor and Welfare of Japan.

6、乙方依据法律法规在日本取得了生产、销售权的汉方药品，依据《日本国医药品海外制造业者认定证》转移至甲方生产并返销日本。

6. The Kampo medicine that Party B has acquired the production and sales rights in Japan in accordance with laws and regulations, which is transferred to Party A for production and resale in Japan in accordance with Certificate of Foreign Manufacturer of Pharmaceutical Products of Japan.

7、丙方在以上前提下同意将商羽控股集团有限公司相当于250万美元的股份转让给乙方，对价以签署本合同日为基准日，最长不超过30日的大自然药业股份有限公司（股票代码为UPC）股价平均值计算。

7. Party C, upon the above premise, agrees to transfer to Party B the equivalent of USD 2.5 million of shares of Sununion Holding Group Ltd., with a consideration calculated on the basis of the average share price of Universe Pharmaceuticals INC (stock code: UPC) for a maximum of 30 days from the date of signing this contract.

五、

V.

1．完成本合同转让之后，丙方在商羽控股集团有限公司的持股比例相应降低，乙方正式成为甲方的注册股东；

1. Upon completion of the transfer hereunder, the shareholding proportion of Party C in Sununion Holding Group Ltd. shall be reduced accordingly and Party B shall officially become the registered shareholder of Party A;

2、叁方约定乙方只对因使用以上规定的无形资产所产生的企业效益部分，按乙方取得的股份比率享受企业股东利润分配权；

2. The three parties agree that Party B shall only enjoy the shareholder’s right of profit distribution in proportion to the shares acquired by Party B in respect of the enterprise benefits generated by the use of the aforesaid intangible assets;

3、叁方约定乙方在没有取得甲、丙方同意的情况下，不得自由转卖其因无形资产投入而取得的股权，在其获得甲、丙方同意转卖此部分股权时，甲、丙方具有优先回购权。如果甲方需要增持或减持大自然药业股份有限公司股份时，乙方同意在保证其所持股份市值不低于250万美元的前提下予以配合。

3. The three parties agree that Party B shall not freely resell the equity acquired from the input of intangible assets without the consent of Party A and Party C. In the event that Party B obtains the consent of Party A and Party C to resell such equity, Party A and Party C shall have the right of first refusal. If Party A needs to increase or decrease its shareholding in Universe Pharmaceuticals INC, Party B agrees to cooperate on the premise that the market value of the shares it holds is not less than USD 2.5 million.

六、若因为法律规定的不可抗力因素或三方认可的原因导致乙方的无形资产无法在本合同中所规定的范围内使用和无法依据乙方的无形资产继续为甲方创造价值时，甲、丙方可以要求乙方退还依据无形资产所取得的相关股份；乙方应当在清算无形资产所形成的价值和确认到甲方不再继续使用本条中无形资产和因此而继续创造价值后，退还依无形资产所取得的甲方相关股份。甲方保证：从要求乙方退还依无形资产所取得的甲方相关股份的意识明确时起及之后，绝对不使用任何内容的研发、生产、质量管理、检验、营销及与本无形资产相关的行为。

VI. In case Party B’s intangible assets cannot be used within the scope specified herein and cannot continue to create value for Party A due to force majeure factors stipulated by law or reasons recognized by the three parties, Party A and Party C may require Party B to return the relevant shares acquired based on the intangible assets. After liquidating the value created by the intangible assets and confirming that Party A will not continue to use the intangible assets herein and continue to create value therefrom, Party B shall return the relevant shares of Party A acquired based on the intangible assets. Party A warrants to use absolutely no content of R&D, production, quality management, inspection, marketing and actions related to the intangible assets from and after the moment when the consciousness of requesting Party B to return the relevant shares of Party A acquired pursuant to the intangible asset becomes clear.

七、甲方承诺：无论乙方通过本合同的履行取得股份数额、比率多少，都将在本合同签署完成后邀请乙方指定人员就任商羽控股集团有限公司董事，保证其至少以该董事身份参加江西大自然制药有限公司的经营与管理；乙方承诺同意以上安排以确保《大自然药业股份有限公司与北日本制药的资本与战略合作合同》目标的推进与实现。

VII. Party A undertakes to, regardless of the amount and ratio of shares acquired by Party B through the performance of the Contract, invite the person designated by Party B to take up the position of director of Sununion Holding Group Ltd. after the signing of the Contract and ensure that he or she will at least participate in the operation and management of Jiangxi Universe Pharmaceuticals Co., Ltd. in the capacity of the said director; Party B undertakes to agree to the above arrangement to ensure the promotion and achievement of the objectives of the Capital and Strategic Cooperation Contract between Universe Pharmaceuticals INC and Kitanihon Pharmaceutical Co., Ltd.

八、甲乙双方一致保证：自本合同签署完成后，任何一方都必须以实现《大自然药业股份有限公司与北日本制药的资本与战略合作合同》的目标为己任，不得违反《大自然药业股份有限公司与北日本制药的资本与战略合作合同》。

VIII. Party A and Party B warrant that, upon the signing of the Contract, either of them shall be responsible for achieving the objectives of the Capital and Strategic Cooperation Contract between Universe Pharmaceuticals INC and Kitanihon Pharmaceutical Co., Ltd., and shall not violate the Capital and Strategic Cooperation Contract between Universe Pharmaceuticals INC and Kitanihon Pharmaceutical Co., Ltd.

九、《大自然药业股份有限公司与北日本制药的资本与战略合作合同》为本合同的上位合同，如若本合同中任何条款与《大自然药业股份有限公司与北日本制药的资本与战略合作合同》相违背，以上位合同为准。

IX. The Capital and Strategic Cooperation Contract between Universe Pharmaceuticals INC and Kitanihon Pharmaceutical Co., Ltd. is the superior contract to the Contract. In case any provision hereunder is contrary to the Capital and Strategic Cooperation Contract between Universe Pharmaceuticals INC and Kitanihon Pharmaceutical Co., Ltd., the latter shall prevail.

签约日期：2021年12月1日

Date of Signing: December 1, 2021

甲方：商羽控股集团有限公司

Party A: Sununion Holding Group Ltd.

法人代表：Gang Lai

Legal Representative: Gang Lai

乙方：北日本制药株式会社

Party B: Kitanihon Pharmaceutical Co., Ltd.

法人代表：Nishimura Ichiro

Legal Representative: Nishimura Ichiro

丙方：赖刚

Party C: Lai Gang

签字：

Signature:

4